Daily Brief Health Care: PHC Holdings , Eli Lilly & Co, Iambic Therapeutics, Novo Nordisk, Cigna Group, Xeris Pharmaceuticals Inc, IHH Healthcare, Imunon and more

• Toho Holdings (8129 JP) has made a non-binding proposal to take PHC Holdings (6523 JP) private at a rumoured valuation of more than JPY200bn, implying JPY1,571 per share.
• KKR and other large holders want an exit, but the rumoured offer is below the last close (JPY1,684) and my fair value range of JPY1,800–2,030.
• The deal fits Toho’s diversification strategy, but funding, 3D Investment Partners’ 24% stake in Toho, and potential competition from domestic funds make completion challenging.

• Eli Lilly and Company has become almost synonymous with the global weight-loss boom, with Zepbound and Mounjaro transforming the company’s growth profile and making obesity one of the biggest stories in healthcare.
• Yet Lilly’s next major growth engine may emerge somewhere completely different.
• CEO David Ricks has indicated that the drugmaker is hunting for additional acquisitions, potentially larger than some of its recent transactions, while pointing to mental health, women’s health and infectious disease as areas where Lilly could make a difference.

• The Platform-Collaboration Pivot Point: Big Pharma’s transition from skeptical “pilot” programs to high-value platform-licensing deals is driven by actual clinical proof-of-concept, rather than speed of in silico discovery. While companies like Iambic have historically secured validation through partnerships with Takeda (up to $1.7 billion in biobucks) and AbbVie, sustained, non-dilutive platform economics require translating AI-designed properties (such as brain penetrance or selective covalent binding) into durable Phase 2/3 human efficacy.
• The Quantitative Algorithmic Edge: Benchmarked against peers like Recursion (which merged with Exscientia in November 2024) and Schrödinger, Iambic’s differentiation lies in its tight physics-ML integration. Models like NeuralPLexer3 and Enchant v3 address multi-parameter optimization (MPO) to reduce the hit-to-lead and lead-optimization phase to under two years—half the traditional timeline. However, this in silico speed has historically had poor translation rates, which Iambic is actively testing in the clinic with IAM1363.
• Capital Constraints of the Dual Strategy: Operating as both a drug developer and a software platform creates severe capital trade-offs. Despite cumulative funding of $461.8 million and a cash balance of $207.9 million as of June 30, 2026, Iambic’s cash burn is escalating rapidly, with a $50.1 million net loss in the first half of 2026 alone. The pending Nasdaq IPO is a necessary step to fund the costly transition of their lead HER2 asset, IAM1363, into registrational trials by early 2027, as non-dilutive collaboration upfronts (e.g., Takeda’s $27 million) are insufficient to sustain multi-asset clinical pipelines.

• Novo Nordisk is escalating its obesity strategy at a time when competition with Eli Lilly is becoming more intense, pricing pressure is rising, and the long-term exclusivity of semaglutide is beginning to weaken in some markets.
• Its latest move is a licensing agreement worth up to $2.6 billion for HRS-1596, an experimental oral GLP-1/GIP drug from Jiangsu Hengrui Pharmaceuticals that could eventually be taken once weekly.
• Only $300 million is being paid upfront, with the balance tied to future development and commercial milestones, but the transaction still highlights how aggressively Novo is searching for the next generation of obesity treatments.

• The Cigna Group is making specialty medicines a central pillar of its next phase of growth, targeting a market that management estimates is approaching $500 billion and expanding at a high-single-digit annual rate.
• These are not everyday prescriptions, but treatments used for complex illnesses such as cancer, cystic fibrosis, hepatitis C and other conditions that often require specialized distribution, monitoring and clinical support.
• Cigna already has a significant position through Accredo Specialty Pharmacy, but its strategy increasingly extends beyond delivering drugs directly to patients.

• Xeris Biopharma Holdings has suddenly become one of the more intriguing names in pharmaceutical M&A after Lundbeck expressed interest in acquiring the commercial-stage drugmaker, even as Xeris maintained that it is not for sale.
• The timing is notable because Xeris is not facing the typical profile of a pressured takeover candidate.
• Its commercial portfolio is expanding rapidly, Recorlev has emerged as the company’s principal growth engine, Gvoke has returned to sequential growth, and Keveyis continues to generate durable rare-disease revenue.

• Iambic Therapeutics is a clinical-stage biotechnology company deploying a differentiated ‘Molecular Superintelligence’ platform that integrates proprietary generative AI physics models (NeuralPLexer, Enchant) with an automated, high-throughput robotic wet lab to execute rapid weekly design-make-test cycles.
• The company’s lead clinical asset, IAM1363—an oral, brain-penetrant, selective Type II HER2/EGFR inhibitor—is demonstrating promising preliminary efficacy and tolerability in Phase 1/1b trials for HER2-altered solid tumors, with pivotal registrational study initiation targeted as early as 2027.
• Backed by over $461 million in equity capital and validated by multi-billion-dollar strategic discovery alliances with AbbVie, Takeda, and Bayer, Iambic offers high platform optionality, balanced against expanding operational R&D cash burn and competitive precision oncology dynamics.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• IHH Healthcare (IHH MK) is facing a legal headwind after a Tokyo District Court dismissed its damage claims against Daiichi Sankyo related to the acquisition of Fortis Healthcare.
• However, accelerated growth momentum reported in 2Q26 financial result, in particular recovery in Singapore operation, raises conviction on the strength of the core operation of IHH.
• Amid rising demand, IHH remains confident in its growth path. The company has reaffirmed 2026 EBITDA and PATMI margins guidance at 22–24% and 8–10%, respectively.

• On September 23, 2026, Imunon, Inc. (IMNN) held an R&D day to review the results for the IMNN-001 program in newly diagnosed advanced ovarian cancer.
• The event included multiple presentations that covered the case for localized IL-12 therapy, translational data that showed IMNN-001 is preferentially taken up by macrophages that leads to local IL-12 expression and remodeling of the tumor microenvironment, final data from the OVATION 2 trial that showed median overall survival was 45.1 months with IMNN-001 plus chemotherapy compared to 30.4 months with chemotherapy alone, and an update on the OVATION 3 trial that includes an enrollment rate of approximately 0.5 patients per site per month compared to a 0.3 planning assumption.
• Lastly, a pre-recorded conversation showcased a participant from the OVATION 1 trial who is now almost 10 years from diagnosis and reports remaining free of cancer recurrence.